Ryan asks Bran if he's going trick-or-treating, but Bran has better things to do...
Sorry that we're a few days late on this Halloween-themed episode, but we really had no other time to film it. Enjoy it belatedly.
(Episode 15 - Season 2)
http://www.ryanandbran.com
Thanks to Red Alien for most of the music. Bit near the end is by Jake Kaufman (virt.vgmix.com). Door sound effects are by Corsica_S and ignotus.
An exclusive Grand Opening was held the evening of May 28th, 2016 in the newly opened FURSAN luxury Flagship Boutique, located on La Croisette18, Parcel 10, Porto Arabia, the Pearl Qatar; a magnificent, luxurious retail environment dedicated to opulence and consummate beauty.
FURSAN, based in Qatar, is the brainchild of Ibrahim Al-Haidos, Founder & Creative Director of the brand and the FURSAN Collection of unrivalled luxury handbags, designed in celebration of the tradition of Dazzah.
Asked what motivated him to design such exquisite, sumptuous handbags, Ibrahim Al-Haidos replied, “I have always had a romantic relationship with commerce and entrepreneurship. Combining my interest in leather goods and fashion, I seek to put Qatar on the luxury fashion map and make it a major destination for luxury brands. I want to give customers the true experience of extravagance by treating them as honored guests when they enter our glorious boutique.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7910551-fursan-grand-opening-flagship-boutique/
Orbis, the international nonprofit that unites the world in the fight against blindness, is proud to land its new, state-of-the-art Flying Eye Hospital in Shenyang, China this week to commence its first training program, running from September 5 - 23. Six years in the making, the third-generation Flying Eye Hospital is the world’s only mobile ophthalmic teaching hospital on board an MD-10 aircraft, donated by FedEx. Hundreds of experts have come together to combine the latest in avionics, hospital engineering, technology and clinical expertise to make the new Flying Eye Hospital a reality. It features modular design, 3D technology and live broadcast capabilities, which enables Orbis and their expert Volunteer Faculty to train more doctors, nurses and healthcare professionals—ultimately treating more people and restoring their sight.
“Today, I am incredibly proud that our Flying Eye Hospital can get to work on its first program,” Bob Ranck, Orbis CEO and President, said. “It is a testament to the hundreds of volunteers, global corporate partners, governments and other individuals who have worked tirelessly to make this unique aircraft a reality, and we thank them one and all. Our mission at Orbis is to bring the world together to fight blindness, and the Flying Eye Hospital is an important tool for achieving this. It is an equal-parts teacher, envoy and advocate for the right to sight. We are excited to start this new chapter in Orbis history here in Shenyang, China.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7316251-orbis-flying-eye-hospital/
Approximately 1.5 million women and girls in the United States have epilepsy, of which nearly 500,000 are women of childbearing age. Treating women with epilepsy, especially women of childbearing age, presents significant challenges to physicians. Epilog.us [http://www.epilog.us], Upsher-Smith Laboratories, Inc’s [http://www.upsher-smith.com] epilepsy-focused educational website, discusses these challenges and provides professional insight by some of the epilepsy community’s most respected physicians including Dr. Cynthia Harden, Chief of the Comprehensive Epilepsy Care Center, North Shore University Hospital and Long Island Jewish Medical Center, and Dr. Christopher Skidmore, Director of Neurology Residency/Assistant Professor of Neurology, at Jefferson Medical College of Thomas Jefferson University.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59306-upsher-smith-epilog-website-challenges-in-managing-women-with-epilepsy
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Many children and teens suffering from tachycardia, or rapid heart rate, have relied on medication to regulate their heart rhythms and control symptoms such as fatigue, dizziness and fainting spells. However, doctors at the Akron Children’s Hospital Arrhythmia Center have made great strides in curing tachycardia with minimally invasive procedures.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51056-akron-childrens-hospital-arrhythmia-tachycardia-cryoablation
Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
http://www.unitetheunion.org BA represents a great British tradition. Unfortunately, Willie Walsh doesnt get it. After taking lawful strike action for the first time in many years, we are being victimized. Brutish Airways is treating us like trash, but we wont give in to a bully. Help us fly the flag and get BA airborne again.
Could migraine patients be doing more to get the most out of their medical visits? According to a new national survey released by the National Headache Foundation (NHF) and GlaxoSmithKline, the answer is yes. For the nearly 30 million migraine sufferers in the U.S., including six million treating with prescription medication, these survey results may have important implications.
The survey, conducted online in November 2010 by Harris Interactive, included 1,218 diagnosed migraine patients taking prescription medications for their migraine attacks as well as 533 physicians who treat between five and 10 migraine patients per week. The findings revealed disparities between what patients and physicians each reported typically discussing during office visits.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glaxosmithkline/48596/
According to Congress’ “Don’t Let the Bed Bugs Bite” Act of 2009, bed bug populations have grown by 500 percent in the United States in recent years, primarily due to increased travel and antique merchandise. Bed bugs are creepy, crawly and hard to kill – an emotional topic that literally and figuratively keeps people up at night. Becoming educated on the bug, its habits, detecting, treating and preventing an infestation is an effective first step to control. Luckily, there is a solution: Ortho Home Defense Max BEDBUG Killer. Take back your bed and keep the critters from turning bedtime into bite time.
To view Multimedia News Release, go to http://www.multivu.com/players/English/47692-Ortho-Home-Defense-Max-BEDBUG-Killer/
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
